Use of Hydrogen Sulphide Donor (N-acetyl Cysteine) in Cases With Acute Ischemic Stroke | NCT07749287

NCT07749287

Overview

NCT ID: NCT07749287
Lead Sponsor: Helwan UniversityOTHER
Official Title: Assessment of Therapeutic Role of H2S Donor in Acute Myocardial Infarction and Acute Cerebral Ischemia: Comparison in Animal Models and Clinical Cases.
Brief Summary: Clarify novel systemic and local inflammatory mechanisms underlying the cross talk between brain and heart ischemic states,

Investigate the new aspects of NAC beyond traditional therapy, in cerebral and myocardial ischemic conditions, both in animal models and clinical cases.
Conditions: Ischemic Cerebral Infarction
Interventions: N Acetyl cysteine 600mg

Status and Timeline

Status: Completed
Last Update Posted: Aug 6, 2026Actual
Start Date: Jun 1, 2021Actual
Primary Completion Date: Jan 1, 2023Actual
Completion Date

Participation Criteria

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Age above 18 years

AIS patients admitted into stroke unit

Onset within 48 hours

Glasgow coma scale (GCS) ≥ 8

Out of window or contraindicated for thrombolytics

Not arrested before

Exclusion Criteria:

Age below 18 years

Cerebral haemorrhage

Dural sinus thrombosis

Glasgow coma scale (GCS) < 8

Patients received thrombolytic

Post arrest

Study Plan

Study Type: Interventional
Phase: Phase 3
Enrollment: 121Actual
Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking

Contacts and Locations

Central Contacts: No data available
Locations: Stroke Unit, Neurology Department, Kasr Al Ainy, Cairo University Hospital

Similar Studies

Participant Group/Arms

Group I (AIS-IHD)Placebo Comparator

critically ill AIS patients who had past history and / or current evidence of IHD (30 patients), With oral saline administration (as a control group).

Drug: Normal (0.9%) saline

Group II (AIS-IHD-NAC)Active Comparator

critically ill AIS patients who had past history and / or current evidence of ischemic heart disease (IHD) (30 patients), With nasogastric or oral administration of NAC.

Drug: N Acetyl cysteine 600mg

Group III (AIS-NON-IHD)Placebo Comparator

critically ill AIS patients who had Neither past history Nor current evidence of IHD (27 patients), With oral saline administration (as a control group).

Drug: Normal (0.9%) saline

Group IV (AIS-NON-IHD-NAC)Active Comparator

critically ill AIS patients who had Neither past history Nor current evidence of IHD (29 patients), With nasogastric or oral administration of NAC.

Drug: N Acetyl cysteine 600mg

NCT04918719Completed

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

NCT01232257Completed

Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)

NCT03320018Completed

Neuroprotection in Acute Ischemic Stroke

NCT01741207Unknown status

Effect of N-acetylcystein in Myocardial Infarction

NCT00868283Completed

The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke

NCT01878344Active, not recruiting

Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention

NCT03915431Active, not recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

NCT04931628Terminated

Efficacy and Safety of Salvianolic Acid on AIS